Gerburg Wulf
Gerburg Wulf
Associate Professor in Medicine, Harvard Medical School
E-mail megerősítve itt: bidmc.harvard.edu
Hivatkozott rá
Hivatkozott rá
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
PJ Lu, G Wulf, XZ Zhou, P Davies, KP Lu
Nature 399 (6738), 784-788, 1999
Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA
A Ryo, F Suizu, Y Yoshida, K Perrem, YC Liou, G Wulf, R Rottapel, ...
Molecular cell 12 (6), 1413-1426, 2003
Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1
GM Wulf, A Ryo, GG Wulf, SW Lee, T Niu, V Petkova, KP Lu
The EMBO journal, 2001
Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC
A Ryo, M Nakamura, G Wulf, YC Liou, KP Lu
Nature cell biology 3 (9), 793-801, 2001
The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production
L Pastorino, A Sun, PJ Lu, XZ Zhou, M Balastik, G Finn, G Wulf, J Lim, ...
Nature 440 (7083), 528-534, 2006
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
WJ Israelsen, TL Dayton, SM Davidson, BP Fiske, AM Hosios, G Bellinger, ...
Cell 155 (2), 397-409, 2013
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
C Pantelidou, O Sonzogni, M De Oliveria Taveira, AK Mehta, A Kothari, ...
Cancer discovery 9 (6), 722-737, 2019
The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response
H Zheng, H You, XZ Zhou, SA Murray, T Uchida, G Wulf, L Gu, X Tang, ...
Nature 419 (6909), 849-853, 2002
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim, J Balmañà, ...
Cancer discovery 2 (11), 1048-1063, 2012
Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton
H Hu, A Juvekar, CA Lyssiotis, EC Lien, JG Albeck, D Oh, G Varma, ...
Cell 164 (3), 433-446, 2016
PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells
A Ryo, YC Liou, G Wulf, M Nakamura, SW Lee, KP Lu
Molecular and cellular biology, 2002
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ...
JAMA oncology 5 (8), 1132-1140, 2019
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ...
Journal of Clinical Oncology 38 (36), 4274-4282, 2020
The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer
G Ayala, D Wang, G Wulf, A Frolov, R Li, J Sowadski, TM Wheeler, KP Lu, ...
Cancer research 63 (19), 6244-6251, 2003
Phosphorylation-specific prolyl isomerization: is there an underlying theme?
G Wulf, G Finn, F Suizu, KP Lu
Nature cell biology 7 (5), 435-441, 2005
Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage
GM Wulf, YC Liou, A Ryo, SW Lee, KP Lu
Journal of Biological Chemistry 277 (50), 47976-47979, 2002
Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer
A Ryo, YC Liou, KP Lu, G Wulf
Journal of cell science 116 (5), 773-783, 2003
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
PK Morrow, GM Wulf, J Ensor, DJ Booser, JA Moore, PR Flores, Y Xiong, ...
Journal of Clinical Oncology 29 (23), 3126-3132, 2011
Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis
G Wulf, P Garg, YC Liou, D Iglehart, KP Lu
The EMBO journal 23 (16), 3397-3407, 2004
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20